Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology is supported by a differentiated menin-inhibitor platform that is translating into strong early commercial traction and compelling clinical validation across AML. Its KOMZIFTI launch showed 115 new patient starts and more than 250 total prescriptions in 2Q26, with management saying it captured the majority of new starts in r/r NPM1-mutant AML while roughly 40% of use involved combination therapy, signaling physician confidence in its safety and combinability. Fundamentally, the bullish outlook rests on the depth and durability of ziftomenib data in KOMET-007, where 96% CRc in NPM1-mutant AML and 94% 12-month OS, alongside a cash position of $519MM to $580.8MM, support a long runway for Phase 3 execution and broader market expansion.

Kura Oncology is viewed negatively because its valuation depends heavily on clinical and regulatory execution in an inherently risky cancer-drug pipeline, where ziftomenib and tipifarnib could fail to show sufficient efficacy or trigger safety concerns that halt development. Its commercial outlook is also uncertain since tipifarnib’s strategy relies on identifying biomarkers and securing patent protection, while FDA and foreign approvals remain unguaranteed and delays could pressure the stock. Despite ending Q2 with $519M in cash/equivalents and $180M in anticipated collaboration payments, the company still posted a $68.3M net loss, or ($0.77) per share, and may need additional financing amid intense competition from larger biotechnology and pharmaceutical peers.